HK1045646A1 - 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法 - Google Patents

蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法

Info

Publication number
HK1045646A1
HK1045646A1 HK02105870.2A HK02105870A HK1045646A1 HK 1045646 A1 HK1045646 A1 HK 1045646A1 HK 02105870 A HK02105870 A HK 02105870A HK 1045646 A1 HK1045646 A1 HK 1045646A1
Authority
HK
Hong Kong
Prior art keywords
methods
preparation
active agents
pharmacologically active
protein stabilized
Prior art date
Application number
HK02105870.2A
Other languages
English (en)
Inventor
P Desai Neil
Tao Chunlin
Yang Andrew
Louie Leslie
Yao Zhiwen
Soon-Shiong Patrick
Magdassi Shlomo
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HK1045646A1 publication Critical patent/HK1045646A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK02105870.2A 1999-05-21 2002-08-12 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法 HK1045646A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US2000/013954 WO2000071079A2 (en) 1999-05-21 2000-05-19 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Publications (1)

Publication Number Publication Date
HK1045646A1 true HK1045646A1 (zh) 2002-12-06

Family

ID=23229970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105870.2A HK1045646A1 (zh) 1999-05-21 2002-08-12 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法

Country Status (5)

Country Link
EP (1) EP1178786A4 (zh)
AU (3) AU784416B2 (zh)
CA (2) CA2371912C (zh)
HK (1) HK1045646A1 (zh)
WO (1) WO2000071079A2 (zh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
AU2002362836B2 (en) 2001-10-15 2008-05-22 Crititech, Inc. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (sl) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2006073154A1 (ja) * 2005-01-07 2006-07-13 Eisai R&D Management Co., Ltd. 医薬組成物及びその製造方法
EP3248600B8 (en) 2005-02-18 2020-06-24 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
AU2006324872B2 (en) * 2005-10-21 2012-03-08 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
WO2008026644A1 (fr) 2006-08-29 2008-03-06 Fujifilm Corporation Matrice hydrophile ayant un composé faiblement soluble dans l'eau scellé à l'intérieur de celle-ci et procédé pour produire celle-ci
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
EP3417859A1 (en) 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
KR20100048751A (ko) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 스프레이 가능한 캡슐화된 기능성 미립자 조성물과 그 제조방법
EP2370060B1 (en) * 2008-11-27 2017-05-03 B.R.A.I.N. Biotechnology Research and Information Network AG Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
KR20120044279A (ko) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 무-프리온 나노입자 조성물 및 방법
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
PT2552438T (pt) 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
JP5926724B2 (ja) 2010-03-29 2016-05-25 アブラクシス バイオサイエンス， エルエルシー がんを処置する方法
US9399071B2 (en) 2010-06-04 2016-07-26 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer
ME03532B (me) 2011-12-14 2020-04-20 Abraxis Bioscience Llc Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje parтikula
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
NZ630392A (en) 2013-03-12 2016-10-28 Abraxis Bioscience Llc Methods of treating lung cancer
WO2014151853A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
CN104548116A (zh) * 2013-10-11 2015-04-29 程树海 一种稳定的蛋白质载药微粒系统制备方法
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES2897991T3 (es) 2015-06-29 2022-03-03 Abraxis Bioscience Llc Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides
AU2016308504A1 (en) 2015-08-20 2018-01-18 Albumedix Ltd. Albumin variants and conjugates
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
DE102016125666A1 (de) * 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
EP3615011A4 (en) * 2017-04-24 2021-01-06 ZY Therapeutics Inc. PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
US20230025865A1 (en) * 2019-12-11 2023-01-26 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas

Also Published As

Publication number Publication date
AU2009217409A1 (en) 2009-10-08
WO2000071079A2 (en) 2000-11-30
AU2006202836A1 (en) 2006-07-27
CA2684454A1 (en) 2000-11-18
WO2000071079A3 (en) 2008-03-27
CA2371912A1 (en) 2000-11-30
AU784416B2 (en) 2006-03-30
EP1178786A4 (en) 2006-03-01
CA2371912C (en) 2010-02-16
EP1178786A1 (en) 2002-02-13
AU2006202836B2 (en) 2009-10-08
AU5035900A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
HK1045646A1 (zh) 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
HK1050367A1 (en) Pharmaceutically active compounds.
SG115489A1 (en) Pharmaceutically active morpholinol
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
ZA200201509B (en) Pharmaceutically active sulfonamide derivatives.
HK1040398A1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0105039A3 (en) Fungicidal propargylether derivatives, preparation and use thereof
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
HK1031725A1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
EP1210084A4 (en) PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
HUP0202377A3 (en) N-substituted perhydrodiazines, preparation and use thereof
ZA200110046B (en) Therapeutic agents.
EP1234834A4 (en) 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
AU2001262699A1 (en) Biologically active agents and drugs
ZA989312B (en) Novel pharmaceutically active compounds, their preparation and use.
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
AUPP899699A0 (en) Peptides, agents and methods
GB9801230D0 (en) Pharmaceutically active morpholinol
IL158978A0 (en) Pharmaceutically active morpholinol